- Billing choices
- 1, 3, 6 or 12 months
- Bottle details
- Confirm volume, concentration and supply period
A nasal offer with several commitments
Effecty's NAD+ nasal spray is a separate prescription offering with monthly and longer-term plans. The currently displayed monthly option is $199 before the introductory discount. We use that recognizable billing interval in the catalog, while explaining the conditional lower headline in the review rather than presenting it as the ordinary renewal price.
Choosing a nasal format changes the practical questions. Readers need the bottle volume, concentration, spray output, storage instructions and intended supply period for the actual preparation. Those details cannot be reconstructed from a subscription price. We have not enrolled with Effecty or verified a dispensed bottle, so this is a documentation review.
Understand the first payment and the next one
The page's approximate $142 headline corresponds to its three-month offer after a $100 first-order discount. The posted $175 monthly equivalent gives a $525 base period, reduced to $425 under that advertised promotion. The calculation explains the headline; it is not evidence that the card will be charged $142 each month.
Effecty also lists six- and twelve-month equivalents of $165 and $160, with their own longer billing intervals. For the monthly option, the advertised first-order reduction is $25. Confirm the chosen total, promotion eligibility and renewal amount on the final order. A discount attached to the first purchase should not enter every month of an annual budget.
The included care pathway
The provider describes a health questionnaire, licensed medical review and shipment if treatment is prescribed. The plan page says shipping and ongoing support are included, and it states that there is no membership fee. These are useful commercial disclosures, although they do not establish the entire clinical experience or guarantee a prescription.
Ask how follow-up works for the nasal product and who can answer pharmacy-specific questions. Find out whether refills require reassessment, how to report an issue with the bottle and what happens to a longer prepaid plan if treatment is stopped. The advertised ability to message a team should be separated from a tested response-time promise.
Convenience does not settle effectiveness
The nasal route avoids an injection step, which may influence someone's preferences. That practical difference does not show equal absorption, equivalent results or lower overall risk compared with every injectable option. We have not verified a head-to-head trial of Effecty's nasal preparation against its injection product.
The company associates NAD+ with cellular energy and longevity, but those broad biological themes do not establish a specific benefit for this bottle. The page acknowledges that the offering is not FDA-approved. A clinician should explain the reason for considering it and the uncertainty around the proposed outcome before price or convenience drives the decision.
Compare bottles and commitments together
The nasal plan becomes easier to evaluate once its prescription quantity is attached to the billing schedule. Another provider may quote a thirty-day bottle, a number of sprays or an unspecified starting package. Record each denominator explicitly instead of assuming all three describe the same amount of treatment.
Effecty provides a useful range of clearly named billing intervals and a visible promotional structure. Its product-level formulation and refund details still need confirmation. A sound shortlist combines those commercial facts with an appropriate clinical discussion, keeping the difference between a convenient delivery method and demonstrated effectiveness clear throughout.
Sources & further reading
Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.